← Leaderboards
Devraj Basu
University Of Pennsylvania
$4,325,199
Attributed
$4,551,935
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $573.5K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,551,935 · 6
By mechanism
R01$2,652,633 · 2
K08$668,790 · 1
R21$453,472 · 1
UH2$414,790 · 1
R56$362,250 · 1
Top collaborators
- Hiroshi Nakagawa2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Meenhard Herlyn$50,214,821
- Chinmay M Trivedi$8,768,083
- Ronen Marmorstein$40,497,435
- Meera Goh Nair$7,363,278
- Hiroshi Nakagawa$10,209,013
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingPathway InteractionsTraitNeoplastic CellGrowthResistanceBaseSurvivorsTumorPatternPhenotypeCancer TherapyCellsMalignant NeoplasmsDisabilityDependenceMalignant Mouth NeoplasmMalignant Epithelial CellSignal TransductionEpigenetic ProcessMouth Squamous Cell CarcinomaNeoplasm MetastasisTumor GrowthTumor Progression
Grant awards (16)
Exploiting differences in HPV oncoprotein function among oropharyngeal cancers to personalize therapy$549,621
R01 · FY2025 · DE · contact PI
Exploiting differences in HPV oncoprotein function among oropharyngeal cancers to personalize therapy$573,512
R01 · FY2024 · DE · contact PI
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery$148,899
UH2 · FY2023 · CA · contact PI
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery$265,891
UH2 · FY2022 · CA · contact PI
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancer$382,375
R01 · FY2021 · DE · contact PI
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancer$382,375
R01 · FY2020 · DE · contact PI
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancer$382,375
R01 · FY2019 · DE · contact PI
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancer$382,375
R01 · FY2018 · DE · contact PI
JARID1B-mediated epigenetic regulation of oncogenic signals in oral cancer$362,250
R56 · FY2017 · DE · contact PI
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance$133,758
K08 · FY2016 · DE · contact PI
A quiescent G0-like cell state as a barrier to eradication oral cancer stem cells$206,736
R21 · FY2015 · DE · contact PI
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance$133,758
K08 · FY2015 · DE · contact PI
A quiescent G0-like cell state as a barrier to eradication oral cancer stem cells$246,736
R21 · FY2014 · DE · contact PI
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance$133,758
K08 · FY2014 · DE · contact PI
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance$133,758
K08 · FY2013 · DE · contact PI
Targeting mesenchymal-like cells in oral cancer to overcome cetuximab resistance$133,758
K08 · FY2012 · DE · contact PI